Gleevec Wins Regular Approval as GIST Adjuvant
WASHINGTON (MedPage Today) — The provisional approval of imatinib (Gleevec) as adjuvant therapy for a certain form of gastrointestinal stromal tumor has been made permanent, the FDA announced.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com